• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 4
  3. Author

Online ISSN: 2515-8260

Volume9, Issue4

PITAVASTATIN AND GEMFIBROZIL AS DRUG REPOSITIONING CANDIDATES FOR ANXIOLYTIC ACTIVITY: AN ANIMAL STUDY BY USING ELEVATED PLUS MAZE

    Dr. Shoebul Haque, Dr. Ajit Mishra, Prof. Narendra Kumar, Dr. Shakita Fatima, Prof. Rishi Pal, Prof. Rajendra Nath, Prof. Amod Kumar Sachan, Prof. Rakesh Kumar Dixit

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 4, Pages 2563-2574

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Anxiety is a common finding in most neurotic disorders and plays a remarkable role in their pathogenesis. [1] Before the 20th century, “anxiety neurosis” and “pantophobia” terms were used to diagnose general anxiety. [2] In most anxiety cases, a person feels worsened episodes of symptoms followed by symptom-free episodes. This condition is referred to as “remitting and relapsing conditions.” [3] The exact cause of anxiety is still a topic of discussion; it may be due to inflection in the central nervous system. [4] Dyslipidemia is a solid soothsayer of persistent medical conditions like obesity that could elevate the risk of anxiety. [5] Several pathways, such as neurotransmitter balance, oxidative stress, and immuno-inflammatory processes associated with anxiety, are also connected with obesity
Keywords:
  • PDF (346 K)
  • XML
(2022). PITAVASTATIN AND GEMFIBROZIL AS DRUG REPOSITIONING CANDIDATES FOR ANXIOLYTIC ACTIVITY: AN ANIMAL STUDY BY USING ELEVATED PLUS MAZE. European Journal of Molecular & Clinical Medicine, 9(4), 2563-2574.
Dr. Shoebul Haque, Dr. Ajit Mishra, Prof. Narendra Kumar, Dr. Shakita Fatima, Prof. Rishi Pal, Prof. Rajendra Nath, Prof. Amod Kumar Sachan, Prof. Rakesh Kumar Dixit. "PITAVASTATIN AND GEMFIBROZIL AS DRUG REPOSITIONING CANDIDATES FOR ANXIOLYTIC ACTIVITY: AN ANIMAL STUDY BY USING ELEVATED PLUS MAZE". European Journal of Molecular & Clinical Medicine, 9, 4, 2022, 2563-2574.
(2022). 'PITAVASTATIN AND GEMFIBROZIL AS DRUG REPOSITIONING CANDIDATES FOR ANXIOLYTIC ACTIVITY: AN ANIMAL STUDY BY USING ELEVATED PLUS MAZE', European Journal of Molecular & Clinical Medicine, 9(4), pp. 2563-2574.
PITAVASTATIN AND GEMFIBROZIL AS DRUG REPOSITIONING CANDIDATES FOR ANXIOLYTIC ACTIVITY: AN ANIMAL STUDY BY USING ELEVATED PLUS MAZE. European Journal of Molecular & Clinical Medicine, 2022; 9(4): 2563-2574.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 50
  • PDF Download: 36
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus